Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: Quinupristin-dalfopristin in combination with minocycline

被引：29

作者：

Raad, I ^{[1
]}

Hachem, R ^{[1
]}

Hanna, H ^{[1
]}

Girgawy, E ^{[1
]}

Rolston, K ^{[1
]}

Whimbey, E ^{[1
]}

Husni, R ^{[1
]}

Bodey, G ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Infect Dis Infect Control & Employee Hlth, Infect Dis Sect, Houston, TX 77030 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2001年 / 45卷 / 11期

关键词：

D O I：

10.1128/AAC.45.11.3202-3204.2001

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Between February 1994 and November 1998, 56 oncology patients infected with vancomycin-resistant enterococci (VRE) were treated with quinopristin-dalfopristin (Q-D) plus minocycline (MIN). Infections included bacteremia, urinary tract infection, pneumonia, and wound infection. The response rate was 68%, and the most frequent adverse event was arthralgia or myalgia (36%). Q-D-MIN is effective for VRE infection in cancer patients but is associated with a substantial frequency of arthralgia or myalgia.

引用

收藏

页码：3202 / 3204

页数：3

相关论文

共 15 条

[1] Treatment of vancomycin-resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristin): A report of fifteen cases [J].

Dever, LL ;

Smith, SM ;

Dejesus, D ;

Masurekar, M ;

Patel, D ;

Kaminski, ZC ;

Johanson, WG .

MICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE, 1996, 2 (04) :407-413

[2] CDC DEFINITIONS FOR NOSOCOMIAL INFECTIONS, 1988 [J].

GARNER, JS ;

JARVIS, WR ;

EMORI, TG ;

HORAN, TC ;

HUGHES, JM .

AMERICAN JOURNAL OF INFECTION CONTROL, 1988, 16 (03) :128-140

[3] Quinupristin-dalfopristin (RP 59500): An injectable streptogramin combination [J].

Griswold, MW ;

Lomaestro, BM ;

Briceland, LL .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1996, 53 (17) :2045-2053

[4] Successful use of tetracycline as therapy of an immunocompromised patient with septicaemia caused by a vancomycin-resistant enterococcus [J].

Howe, RA ;

Robson, M ;

Oakhill, A ;

Cornish, JM ;

Millar, MR .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (01) :144-145

[5]

KOLL BS, 1993, CLIN INFECT DIS S2, V17, P322

[6] SEMIQUANTITATIVE CULTURE METHOD FOR IDENTIFYING INTRAVENOUS-CATHETER-RELATED INFECTION [J].

MAKI, DG ;

WEISE, CE ;

SARAFIN, HW .

NEW ENGLAND JOURNAL OF MEDICINE, 1977, 296 (23) :1305-1309

[7] Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents [J].

Matsumura, SO ;

Louie, L ;

Louie, M ;

Simor, AE .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (11) :2776-2779

[8] Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin) [J].

McNeil, SA ;

Clark, NM ;

Chandrasekar, PH ;

Kauffman, CA .

CLINICAL INFECTIOUS DISEASES, 2000, 30 (02) :403-404

[9] ACTIVITY OF TETRACYCLINE, DOXYCYCLINE, AND MINOCYCLINE AGAINST METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT STAPHYLOCOCCI [J].

MINUTH, JN ;

HOLMES, TM ;

MUSHER, DM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1974, 6 (04) :411-414

[10] The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium [J].

Moellering, RC ;

Linden, PK ;

Reinhardt, J ;

Blumberg, EA ;

Bompart, F ;

Talbot, GH .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (02) :251-261